Trimel BioPharma (Trimel) is focused on improving the utility of known pharmaceutical compounds by employing 21st century dosing technologies that are specifically designed to avoid first pass metabolism. These Localized Dosing Technologies (LDT) allow Trimel to precisely target the distribution of medications reducing side effects and improving patient outcomes.

Trimel currently has the rights to three proprietary LDT platforms and is actively pursuing the development and application of these technologies to several high value high volume pharmaceutical compounds.

Trimel brings together a best-in-class leadership team, with significant expertise in formulation, clinical design, regulatory affairs, manufacturing, marketing and business development that will maximize the value of its technology platforms and ultimately the medications currently under development.

New!  Trivair Technology Overview